CY1113207T1 - Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη - Google Patents

Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη

Info

Publication number
CY1113207T1
CY1113207T1 CY20121100881T CY121100881T CY1113207T1 CY 1113207 T1 CY1113207 T1 CY 1113207T1 CY 20121100881 T CY20121100881 T CY 20121100881T CY 121100881 T CY121100881 T CY 121100881T CY 1113207 T1 CY1113207 T1 CY 1113207T1
Authority
CY
Cyprus
Prior art keywords
suspension
dosage form
proton pump
solid dosage
form containing
Prior art date
Application number
CY20121100881T
Other languages
English (en)
Inventor
Eva Persson
Eva Trofast
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36602062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113207(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1113207T1 publication Critical patent/CY1113207T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Μία στερεή, γρήγορης πηκτωμάτωσης φαρμακευτική διά στόματος μορφή δοσολογίας, καθώς και υδατικά εναιωρήματα που παρασκευάζονται από αυτή, η οποία περιέχει έναν ευαίσθητο στο οξύ αναστολέα αντλίας πρωτονίων ως ενεργό συστατικό που διανέμεται σε ένα πλήθος από οξυανθεκτικά σύμπηκτα και μία κοκκώδης ουσία ρύθμισης εναιωρήματος που περιέχει έναν διαλύτη γρήγορης διάλυσης, κοκκοποιημένο μαζί με ένα πηκτικό μέσο που επιλέγεται από ξανθανικά κόμμι και ένα όξινο μέσο ρύθμισης pΗ και μία συνδετική ουσία. Η κοκκώδης ουσία ρύθμισης εναιωρήματος καταθρυμματίζεται γρήγορα και εναιωρείται σε ένα υδατικό μέσο, σχηματίζοντας έτσι ένα ομοιογενές σταθερό και ισχυρό εναιώρημα που έχει αναπαράξιμο ιξώδες. Επιπλέον, η εφεύρεση σχετίζεται με μία βελτιωμένη διαδικασία για την παρασκευή της και την χρήση τέτοιας μορφής σε ιατρικές θεραπείες που περιλαμβάνει την πρόληψη των γαστρεντερικών διαταραχών στους ανθρώπους.
CY20121100881T 2004-12-22 2012-09-26 Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη CY1113207T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63843504P 2004-12-22 2004-12-22
EP05820824A EP1830816B1 (en) 2004-12-22 2005-12-20 Solid dosage form comprising proton pump inhibitor and suspension made thereof

Publications (1)

Publication Number Publication Date
CY1113207T1 true CY1113207T1 (el) 2016-04-13

Family

ID=36602062

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100881T CY1113207T1 (el) 2004-12-22 2012-09-26 Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη

Country Status (30)

Country Link
US (5) US20060134210A1 (el)
EP (1) EP1830816B1 (el)
JP (1) JP5171259B2 (el)
KR (1) KR101321641B1 (el)
CN (1) CN101087590B (el)
AR (1) AR052173A1 (el)
AU (1) AU2005319732B2 (el)
BR (1) BRPI0519186A2 (el)
CA (1) CA2592030C (el)
CY (1) CY1113207T1 (el)
DK (1) DK1830816T3 (el)
ES (1) ES2389844T3 (el)
HK (2) HK1111609A1 (el)
HR (1) HRP20120719T1 (el)
IL (1) IL183658A (el)
ME (1) ME01458B (el)
MX (1) MX2007007423A (el)
MY (1) MY149156A (el)
NO (1) NO20073731L (el)
NZ (1) NZ555833A (el)
PL (1) PL1830816T3 (el)
PT (1) PT1830816E (el)
RS (1) RS52472B (el)
RU (1) RU2397756C2 (el)
SA (1) SA05260421B1 (el)
SI (1) SI1830816T1 (el)
TW (1) TWI478735B (el)
UA (1) UA87341C2 (el)
WO (1) WO2006068596A1 (el)
ZA (1) ZA200705113B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
AU2006236564B2 (en) * 2005-04-15 2011-02-17 Tolmar, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
US8247440B2 (en) 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
WO2009114365A2 (en) * 2008-03-13 2009-09-17 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP2012072061A (ja) * 2009-01-29 2012-04-12 Eisai R & D Management Co Ltd 新規組成物
EP2544665A4 (en) * 2010-03-11 2014-01-01 Rich Vitamins Llc NUTRITIONAL POWDER WITH RAPID DISSOLUTION
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
HRP20230250T1 (hr) 2015-07-17 2023-04-14 BE Pharbel Manufacturing Višeslojni farmaceutski aktivne mikročestice, koje otpuštaju spoj u tekućem obliku doziranja
EP3117824A1 (en) 2015-07-17 2017-01-18 BE Pharbel Manufacturing Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form
US10736855B2 (en) * 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN107468652A (zh) * 2016-06-07 2017-12-15 北京新领先医药科技发展有限公司 一种固体干混悬温敏凝胶剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018065953A1 (en) * 2016-10-06 2018-04-12 Jubilant Generics Limited Pharmaceutical suspension dosage form of benzimidazole compounds and process of preparation thereof
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
CN108201527A (zh) * 2016-12-16 2018-06-26 广州共禾医药科技有限公司 一种包含质子泵抑制剂的缓释干混悬剂及其制备方法
JP6964369B1 (ja) * 2021-02-10 2021-11-10 共和薬品工業株式会社 速崩壊性ゲル皮膜

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1183574B (it) * 1985-05-08 1987-10-22 Eurand Spa Metodo per ottenere una sospensione estemporanea omogenea di microcapsule
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
GB8628359D0 (en) * 1986-11-27 1986-12-31 Zyma Sa Galenical formulation
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
US5288500A (en) * 1987-03-13 1994-02-22 Benzon Pharma A/S Oral composition containing particles comprising an active substance
IT1246350B (it) * 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
JP3802555B2 (ja) * 1991-12-17 2006-07-26 フイズ テクノロジーズ リミテッド 潰瘍予防及び治療組成物並びに方法
SE9301489D0 (sv) * 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) * 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
US6362009B1 (en) * 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
SI1037634T1 (sl) * 1997-12-08 2006-02-28 Altana Pharma Ag Peroralna dajalna oblika, ki obsega inhibitor protonske crpalke (npr. pantoprazol)
US6013821A (en) * 1998-06-25 2000-01-11 Abbott Laboratories Removal of silylated compounds from solvent and gas waste streams
US6194395B1 (en) * 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
ATE300285T1 (de) * 1999-06-07 2005-08-15 Altana Pharma Ag Neue zubereitung und darreichungsform enthaltend einen säurelabilen protonenpumpeninhibitor
ES2304980T3 (es) * 1999-09-30 2008-11-01 Penwest Pharmaceuticals Co. Sistemas de matriz de liberacion sostenida para farmacos altamente solubles.
PT1232746E (pt) * 2001-02-14 2006-11-30 Forte Iq B V Composição farmacêutica que compreende goma xantana
TWI259836B (en) * 2001-04-12 2006-08-11 Astrazeneca Ab Modified release formulation suitable for antiarrhythmic compounds
US6605302B2 (en) * 2001-07-17 2003-08-12 Osmotica Corp. Drug delivery device containing oseltamivir and an H1 antagonist
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040081700A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Dose titratable liquid dosage forms of acid labile drugs
WO2005011637A1 (ja) * 2003-08-04 2005-02-10 Eisai Co., Ltd. 用時分散型製剤
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
MX2008000680A (es) * 2005-07-15 2008-03-14 Wyeth Corp Inhibidor de la retoma dual de norepinefrina y serotonina altamente selectivo y su uso.

Also Published As

Publication number Publication date
SI1830816T1 (sl) 2012-10-30
NZ555833A (en) 2009-10-30
DK1830816T3 (da) 2012-10-01
US20080020053A1 (en) 2008-01-24
ME01458B (me) 2014-04-20
ES2389844T3 (es) 2012-11-02
RS52472B (en) 2013-02-28
EP1830816A1 (en) 2007-09-12
CA2592030C (en) 2014-01-28
AU2005319732A1 (en) 2006-06-29
MY149156A (en) 2013-07-15
TW200635618A (en) 2006-10-16
IL183658A0 (en) 2007-09-20
KR20070094610A (ko) 2007-09-20
NO20073731L (no) 2007-09-24
MX2007007423A (es) 2007-07-17
HK1111609A1 (en) 2008-08-15
RU2007127781A (ru) 2009-01-27
EP1830816B1 (en) 2012-08-01
SA05260421B1 (ar) 2010-03-08
TWI478735B (zh) 2015-04-01
US20150079186A1 (en) 2015-03-19
US20130273168A1 (en) 2013-10-17
UA87341C2 (uk) 2009-07-10
US20170165248A1 (en) 2017-06-15
HRP20120719T1 (hr) 2012-10-31
JP5171259B2 (ja) 2013-03-27
ZA200705113B (en) 2009-12-30
PL1830816T3 (pl) 2012-11-30
KR101321641B1 (ko) 2013-10-22
AR052173A1 (es) 2007-03-07
JP2008525433A (ja) 2008-07-17
CN101087590B (zh) 2012-06-13
CA2592030A1 (en) 2006-06-29
RU2397756C2 (ru) 2010-08-27
US20060134210A1 (en) 2006-06-22
BRPI0519186A2 (pt) 2008-12-30
CN101087590A (zh) 2007-12-12
EP1830816A4 (en) 2011-06-15
IL183658A (en) 2014-04-30
HK1115308A1 (en) 2008-11-28
WO2006068596A1 (en) 2006-06-29
PT1830816E (pt) 2012-09-11
AU2005319732B2 (en) 2008-12-11

Similar Documents

Publication Publication Date Title
CY1113207T1 (el) Στερεη μορφη δοσολογιας που περιεχει αναστολεα αντλιας πρωτονιων και εναιωρημα που παρασκευαζεται απο αυτη
WO2007027941A3 (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
TR200801336T1 (tr) Kararlılığı artmış zayıf su çöznurluğune sahip ilaçların preparasyonuna yönelik kompozisyonlar ve yöntemler.
BRPI0414581A (pt) derivados de benzimidazol: preparação e aplicações farmacêuticas
HUP0302857A2 (hu) Gyógyszerészeti kiszerelés
EA200800360A1 (ru) Формуляции с высоким содержанием лекарства и дозированные формы
CY1109011T1 (el) ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ βd ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΔΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
CY1115709T1 (el) Φαρμακευτικη μορφη περιεχουσα φλουπιρτινη με ελεγχομενη αποδεσμευση της δραστικης ουσιας
CY1116840T1 (el) Χρηση 24-norudca
DK1359939T3 (da) Sammensætning og fremgangsmåde til potensering af lægemidler
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EA201070194A1 (ru) Стабильная жидкая фармацевтическая композиция на основе тразодона
EA200900531A1 (ru) Фармацевтические составы
ES2549309T3 (es) Formulación terapéutica nueva
EA200800150A1 (ru) Состав с пролонгированным высвобождением действующих начал лекарственного средства
WO2006111853A3 (en) Stable solid dosage forms of acid labile drug
EA200701735A1 (ru) Композиция, содержащая хитозан, для пролонгированного высвобождения лекарственного средства
TH80311A (th) รูปแบบขนาดยาของแข็งที่ประกอบรวมด้วยตัวยับยั้งการปั๊มโปรตอนและสารแขวนตะกอนที่ทำจากรูปแบบขนาดยาดังกล่าว
EA200801449A1 (ru) Разрывные гранулы
UY29289A1 (es) Forma de dosificación sólida que comprende un inhibidor de la bomba de protones y una suspensión obtenida a partir de la misma
EA201391369A1 (ru) Пероральные фармацевтические дисперсные композиции
GR1004331B (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν αλας αλενδρονικου οξεος
AR046709A1 (es) Preparacion farmaceutica solida
TH80311B (th) รูปแบบยาของแข็งที่ประกอบรวมด้วยตัวยับยั้งการปั๊มโปรตอนและยาแขวนตะกอนที่ทำจากรูปแบบยาดังกล่าว